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Abstract 
The aggregation of specific proteins plays a pivotal role in the etiopathogenesis of several 
neurodegenerative diseases (NDs). β-Amyloid (Aβ) peptide-containing plaques and intraneuronal 
neurofibrillary tangles composed of hyperphosphorylated protein tau are the two main 
neuropathological lesions in Alzheimer’s disease. Meanwhile, Parkinson’s disease is defined by the 
presence of intraneuronal inclusions (Lewy bodies), in which α-synuclein (α-syn) has been identified 
as a major protein component.  
The current literature provides considerable insights into the mechanisms underlying oligomeric-
related neurodegeneration, as well as the relationship between protein aggregation and ND, thus 
facilitating the development of novel putative biomarkers and/or pharmacological targets.  
Recently, α-syn, tau and Aβ have been shown to interact each other or with other “pathological 
proteins” to form toxic heteroaggregates. These latest findings are overcoming the concept that each 
neurodegenerative disease is related to the misfolding of a single specific protein. 
In this review, potential opportunities and pharmacological approaches targeting α-syn, tau and Aβ 
and their oligomeric forms are highlighted with examples from recent studies. Protein aggregation as 
a biomarker of NDs, in both the brain and peripheral fluids, is deeply explored. Finally, the 
relationship between biomarker establishment and assessment and their use as diagnostics or 
therapeutic targets are discussed. 
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1. New insights into protein aggregation-related neurodegenerative diseases 
Neurodegenerative diseases (NDs) are characterized by the dysfunction and loss of neurons in 
specific areas and are associated with pathologically misfolded proteins that accumulate in the human 
brain and in peripheral organs [1-3]. Although these diseases are distinguished by specific clinical 
signs and symptoms, NDs share conspicuous similarities and have been defined as “proteinopathies”, 
which include Alzheimer’s disease (AD); Parkinson’s disease (PD); all the synucleinopathies; 
transmissible spongiform encephalopathies (TSEs; also known as prion diseases); amyotrophic lateral 
sclerosis (ALS); Dementia with Lewy body (DLB) and frontotemporal dementia (FTD).  
The molecular classification of NDs relies upon meticulous morphological evaluation of protein 
aggregates, their distribution within the brain, genetic alterations and clinical symptoms. Each of 
these diseases has been generally related to specific type of protein aggregates. For example, β-
amyloid1-42 (Aβ) and tau protein represent the principal constituent of AD pathological hallmarks. Aβ 
aggregates to form extracellular deposits called senile plaques (SP) (Fig. 1); simultaneously, tau 
produces intraneuronal neurofibrillary tangles (NFTs), composed of abnormal filaments of 
hyperphosphorylated protein (Fig. 1) [4].  
Conversely, α-syn has been generally associated with PD, DLB, and glial cytoplasmic inclusions in 
Multiple System Atrophy (MSA). The common hallmarks of these pathologies are the abnormal 
accumulation of misfolded α-syn forming amyloid fibrils which subsequently accumulate in Lewy 
Bodies (LB) and Lewy neurites (LN) [5]. 
Post-mortem analyses commonly identify a mixed pattern of proteinopathies, frequently 
accompanied by signs of chronic cerebrovascular disease pathology [6]. Moreover, in addition to 
homoaggregates, monomers of a single protein could also aggregate with other misfolded proteins 
leading to the formation of heteroaggregates [7, 8]. This evidence has provided a link between the 
different NDs. 
In this review, the most current studies on protein aggregation in NDs will be summarized, with a 
specific focus on linking protein oligomerization to the molecular classification of NDs. Because the 
combination of proteinopathies is an emerging topic in the recent literature, our commentary will 
place an emphasis on the roles of mixed oligomers and heteroaggregation as biomarkers and 
innovative targets of NDs with a focus on AD and PD.  
 
1.1 Protein aggregation in neurodegenerative diseases: oligomers and heteromers 
1.1.1. Aβ, tau and α-syn misfolding in oligomeropathies 
Several efforts have been directed towards establishing an understanding of prion protein folding and 
the structural features of prion proteins after oligomerization and aggregation [9]. The detailed 
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mechanisms of aggregation have been extensively described in recent reviews [10-13]. Briefly, the 
pathological mechanisms responsible for the gradual transition from a highly soluble, functional 
conformation to an insoluble, filamentous pathological aggregate containing characteristic cross-β-
sheet structures are not completely understood [14]. The accumulation of protein aggregates increases 
with age as the ubiquitin/proteasome system [15] and autophagy processes [16] lose their ability to 
control and degrade misfolded monomers (Fig. 1).  
Although there is considerable information regarding oligomers and fibril structures [17], the toxic 
types of prion proteins and the mechanisms underlying their cytotoxicity are still being evaluated. 
The oligomeric structures of A are soluble in nature and considerably the most toxic of all the 
aggregate types [11].  
Conversely, α-syn generates oligomeric species, protofibrils and fibrils similar to A but with slower 
kinetics [18], and its toxic forms consist of oligomers rather than fibrils. In particular, the non-amyloid 
component (NAC) of the central α-syn fibrillogenic fragment has been established to directly induce 
toxic effects (Fig. 1) [19, 20]. 
Tau phosphorylation in specific sites has been shown to direct proteins to aggregate [21] by 
decreasing their affinity for microtubules [22]. For this reason, tau hyperphosphorylation is the 
hallmark of all tauopathies, even though hyperphosphorylation states differ among and within 
different pathologies [23]. The identity of the toxic form of tau is still actively debated, but the most 
toxic form appears to be the oligomeric form [24-26]. 
Despite the aforementioned differences between Aβ, α-syn and tau, they share a common hypothesis: 
smaller diffusible oligomers rather than the insoluble cross β-sheet amyloid fibrils drive the 
degenerative process [27]. The current hypothesis states that oligomeric forms are produced by 
monomeric aggregation but could result from either fragmentation of preformed fibrils or 
unsuccessful degradation of fibrils by lysosomes or the proteasome.  
Several microenvironmental factors and intracellular mechanisms have been proposed as triggers for 
spreading the aggregation process; however, it is difficult to determine whether the presence of these 
protein aggregates is a consequence or a cause. The misfolding of disease-specific proteins has been 
correlated with neuroinflammatory processes [28], increased levels of oxidative stress [29], vascular 
degeneration [30], and neuronal cell death [31]. However, even if the involved proteins differ among 
the NDs, the common feature remains oligomer toxicity. This evidence led to the generation of the 
term “oligomeropathies”, which is a better description of all the protein misfolding-related diseases 
[32, 33]. 
 
1.1.2 Aβ, tau and α-syn heteroaggregation 
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In addition to the co-existence of plaques, tangles and LBs, the recent literature has indicated that Aβ, 
tau, and α-syn promote the accumulation of one another [34-36], which creates a vicious cycle in ND 
pathogenesis and supports the hypothesis that structural and functional cooperation occur between 
misfolded proteins. For example, α-syn has been demonstrated to promote tau polymerization or its 
in vivo accumulation [34, 36].  
Aβ has been shown to influence α-syn and tau aggregation as well. For example, double-transgenic 
α-syn/amyloid precursor protein (APP) mice exhibit enhanced α-syn deposition compared to single-
transgenic mice [37]. Moreover, using a genetic approach to combine the pathologies of AD and 
dementia with Lewy bodies, Clinton and co-workers have confirmed that Aβ, tau, and α-syn interact 
in vivo to promote the aggregation and accumulation of one another and accelerate cognitive 
dysfunction [36]. 
The hypothesis of the structural and functional cooperation between misfolded proteins has been 
confirmed by several clinical observations demonstrating a high comorbidity and overlapping 
between pure synucleinopathies and tauopathies. Indeed, the co-occurrence of tau and α-syn 
inclusions is frequent in several NDs, such as PD, DLB, a Lewy body variant of AD [38, 39], and 
even Down’s syndrome [38, 40]. Furthermore, α-syn seems to contribute to AD pathogenesis as well 
[6, 41], with 30 – 40% of AD cases presenting with LB and LN [42]. 
In addition to oligomers of the same protein, the role of heterocomplexes in NDs has also been 
emerging. Aβ and α-syn have been shown to form complexes and co-immunoprecipitate from patient 
brain samples and transgenic mouse models, providing clear evidence for their direct interaction (Fig. 
1) [43, 44]. Aβ accumulates primarily in the extracellular regions, but it has also been found in 
different subcellular areas, including mitochondria and the Golgi apparatus [45]. This abnormal 
localization allows Aβ to interact with a variety of intracellular proteins, including α-syn [43, 44]. In 
physiological condition, α-syn, in a helical conformation, is associated with dopamine containing 
vesicles and is involved in the vesicle transport process. When the vesicles are fused to the membrane, 
α-syn is completely released into the cytosol and is absent in the synaptic membrane [46]. In 
pathological conditions with neuronal damage, α-syn tends to increase and to from cytosolic 
aggregates, which interact with membrane-associated Aβ40 and Aβ42 peptides [47]. Membrane-bound 
α-syn associates with A peptides at multiple locations. Mandal and co-workers [43] have 
demonstrated with NMR experiments that both 15N-labelled A40 and A42 interact with membrane-
associated α-syn, particularly with the latter (81–95) residues, as confirmed by a solid phase binding 
assay [46]. α-Syn-induced structural alteration is more substantial in combination with A42 
compared to A40, as demonstrated in transgenic mice [37] and indicates a greater pathogenic role 
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for A42. Of note, the three residues involved in α-syn-A42 interaction (residues G67, G73 and V74) 
[43] belong to the NAC component of α -syn. Considering that the NAC contributes up to 10% of the 
SDS-insoluble protein in amyloid plaques [43] and that α-syn is expressed in regions of the brain 
characterized by abundant AD lesions, the interaction between the two proteins might play a key role 
in both DLB and AD pathogenesis.  
α-Syn has been demonstrated to promote tau polymerisation in vitro and to co-localize with the same 
protein in neurons [34, 48]. α-Syn is known as a preterminal protein and is not expected to co-localize 
with tau in the axon. However, Jakes and co-workers [49] have provided evidence of axonal α-syn 
transport in the rat optic system, suggesting that the two proteins have wide opportunities for 
interactions within the axonal compartment. In particular, in the same study the authors identified the 
microtubule binding (MT)-binding protein tau as a ligand for the C-terminus of α-syn in human brain 
cytosol and established the direct protein interaction (Fig. 1) [49]. Affinity chromatography 
experiments have confirmed that α-syn directly binds to tau and induces fibrillation [49]. In different 
cellular systems, the physical interaction between the two proteins has been demonstrated to be 
abolished by the most common tau mutation (P301L) associated with frontotemporal dementia [50]. 
Interestingly, high tubulin concentrations, present in microtubules, has been shown to inhibit α-syn 
binding to tau, indicating that α-syn is a ligand for the soluble tau pool in contrast to the protein 
phosphatases 1 and 2A [51, 52]. 
In conclusion, there is mounting evidence of protein heteromers playing a role in ND pathogenesis. 
The stoichiometry of the interaction among the misfolded proteins and the correlation between the 
content of heteroaggregates and ND progression are currently unknown. 
 
2. Biomarkers of protein aggregation-related neurodegenerative diseases 
The pathological processes that characterize NDs begin decades before the first symptoms of 
cognitive dysfunction, thus making it difficult to identify pathology based on the clinical phenotype 
alone. For this reason, ND management would strongly benefit from the availability of biomarkers 
(BMs) for early diagnosis [53]. A biomarker is defined as an indicator of normal biological processes, 
pathological processes or of pharmacological responses to a therapeutic intervention [54]. 
The most attention has been focused on identifying genes that may be causative or associated with 
specific diseases and on unravelling the functional mechanisms induced by products of those genes 
as BMs for early diagnosis. In regards to AD, the identification of Aβ precursor protein (APP) and 
presenilin 1 and 2 mutations has supported the amyloid hypothesis and identified potential targets for 
pharmacological interventions. In particular, the genetic association with enhanced AD risk in 
families that carry the apolipoprotein E ε4 allele remains the primary issue [55]. However, it should 
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be emphasized that mutations in these genes identify at-risk family members but are not applicable 
to sporadic forms of AD [56, 57]. 
In contrast, five pathogenic mutations in genes linked to familial PD have been identified: autosomal 
dominant LRRK2 and SNCA, autosomal recessive Parkin, PINK1 and DJ1 [58, 59]. In addition, 
mutations in α-syn, parkin, ubiquitin c-terminal hydrolase (UCH)-L1 and DJ-1 have been linked to 
juvenile forms of PD [53]. 
 
2.1 Neuroimaging and central biomarkers 
Potential central and peripheral biomarkers and the respective methodology of identification are 
summarized in Table 1.  
During the past decade, the phenotype of NDs has been defined extensively by neuroimaging 
techniques, both in preclinical and early clinical disease stages. A plaques in post-mortem studies 
were first detected using coloured dyes, such as Congo red [60], and fluorescent dye, such as 
Thioflavin-T (ThT) [61], that are capable of binding the -sheet structure of A. Such compounds 
have been utilized in the development of the first radiolabelled molecules for positron emission 
tomography (PET), including 2-(1-(6-[(2-[18F]-fluoroethyl)(methyl)amino]-2-
naphthyl)ethylidene)malononitrile ([18F]-FDDNP), that can detect SP in AD patients [62]. Novel in 
vivo imaging techniques have been used to detect pathogenic Aβ accumulation, providing novel AD 
diagnostics and offering a new instrument to track changes in amyloid plaques in response to amyloid-
lowering therapeutics. In particular, researchers have identified a Thioflavin-T analogue that can bind 
β-sheet–rich fibrils [63], which allows PET visualization of amyloid burden. Another example is the 
benzothiazole derived [11C]-Pittsburgh compound B PET ([11C]-PiB), which crosses the blood–brain 
barrier and binds amyloid deposits in the brain parenchyma where binding of carbon-11-PIB can be 
detected by PET imaging. Promisingly, an inverse correlation has been demonstrated between [18F]-
2-fluoro-deoxy-D-glucose PET imaging of glucose metabolism and PiB binding in the parietal cortex 
[64]. Conversely, no clinical studies on Aβ imaging using magnetic resonance imaging (MRI) have 
been reported, even though fluorine-19 ([19F]) probes capable of detecting Aβ deposition have been 
in development in mouse models of AD [65-69].  
Among all the efforts in the development of tracers to detect Aβ, only three probes have been 
approved by the European Medicines Agency and the Food and Drug Administration in the 
USA:[18F]-florbetapir (Amyvid®) [70], [18F]-flutemetamol (Vizamyl®) [71], and [18F]-florbetaben 
(Neuraceq®) [72]. 
Finally, [18F]-FDG PET has been used to trace and visualize the ‘typical’ metabolic deficiencies of 
AD, which allows it to be distinguished from other ND [73, 74]. In addition, AD and forms of vascular 
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dementia can be distinguished in regional cerebral perfusion studies by single photon emission 
computed tomography (SPECT) [75]. 
Beyond AD, the aforementioned PET tracers allow for exceptional in vivo research of other 
pathological conditions characterized by A deposition, including cerebral amyloid angiopathy, brain 
trauma, Down’s syndrome, and even cardiac amyloidosis [76-78]. 
Tau is a more complex target than A, because of its intracellular localization, the existence of six 
dissimilar isoforms in different diseases, and its lower concentration. For these reasons, the 
requirements for a tau PET tracer are more stringent [79]. However, due to the unique role of this 
protein as a marker of neurodegeneration, the imaging of tau will allow for topographic distribution 
of tau proteins across diseases and in vivo assessment of tau pathology evolution. Furthermore, PET-
tau could allow for precocious and precise diagnosis and monitoring of disease progression in 
tauopathies, cognitive impairment, movement disorders, and trauma [79]. Finally, the combination 
of Aβ and tau-PET will expand knowledge of the interactions between the two proteins in humans. 
To date, none of the tau imaging compounds described in preclinical and clinical studies have been 
approved. Among the more selective binders, [11C]-PBB3 has been shown to allow tau imaging in 
AD and non-AD tauopathies [80]. Moreover, the 18F-labelled tracers [18F]-THK-5351 and [18F]-
AV1451 have been demonstrated to align with the known distribution of tau neurofibrillary tangles 
in live patients [81-83]. Additionally, [125I]-phenylethenyl benzimidazole is currently under 
development for the detection of NFTs with SPECT [84]. 
Similarly, PD imaging includes either detecting alterations in brain structure or examining functional 
changes in brain metabolic patterns. Recently, a significant increase over controls in soluble α-syn 
levels has been found in AD brains, which correlates with cognitive impairment better than soluble 
Aβ or tau levels [41]. Based on these data, researchers are trying to develop α-syn imaging agents 
that could be useful for PD diagnosis as well. Furthermore, α-syn has advantages over dopamine as 
a biomarker for PD, because changes in α-syn often occur earlier than those in dopamine and are not 
affected by symptomatic treatment. Agents that bind brain α-syn would allow tracking of disease 
severity and localization, as well as monitoring of the therapeutic effects of compounds targeting α-
syn. Thus, the Michael J. Fox Foundation has assembled a consortium of researchers to develop an 
α-syn PET radiotracer [85]. 
Studies focusing on the development of PET or SPECT tracers for α-syn are ongoing but are still in 
their infancy [86]. For example, [18F] 3-(2-fluoroethoxy)-7-nitro-10H-phenothiazine and [11C]-3-
methoxy-7-nitro-10H-phenothiazine have been identified as more specific binders for α-syn and can 
cross the blood–brain barrier in animals [87]. However, these compounds have not been applied to 
human imaging yet.  
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Nevertheless the great efforts, the establishment of routinely biomarkers remains a strenuous 
objective, due to the dynamic anatomic localization and content of the different protein aggregates. 
 
2.2 Peripheral biomarkers  
Several studies have demonstrated that ND pathology and biomarkers are not restricted to the brain 
and that substantial biological changes appear in peripheral tissues as well. In particular, the typical 
brain alterations of NDs have been found, at the molecular level, in cerebrospinal fluid (CSF). For 
this reason, this fluid has been heavily studied in the search for ND biomarkers. CSF biomarkers 
should also reproduce brain pathological processes, such as synaptic/axonal degeneration, Aβ 
oligomerization, tau hyperphosphorylation, and α-syn accumulation [53]. Among CSF biomarkers, 
Aβ42, total tau and α-syn are the most studied (Table 1).  
In AD, a decrease in CSF Aβ42 has been found [88, 89]. This reduction could be due to the deposition 
of the monomers in brain plaques that limit their diffusion to the CSF. Additional reasons include the 
detection limits of ELISA, which can be caused by Aβ42 binding to other proteins that block antibody 
recognition or lack of recognition of the Aβ oligomer by the ELISA that generates false negatives 
[53]. Aβ1-40 (Aβ40), which is the most abundant amyloid form, has been found to be unaffected or 
marginally augmented in AD [90], consistent with the decreased Aβ42/Aβ40 ratio in the CSF of AD 
patients [91]. Aβ reduction has also been demonstrated in patients with FTD and vascular dementia, 
even if current measurements are insufficient to distinguish them from AD [92].  
Contradictory data have been reported regarding the correlation between Aβ CSF concentrations and 
cognitive performance in AD: non-significant [93], inversely correlation [94] or even directed 
relationships [95] have been found. Based on these findings, the putative value of Aβ in AD 
progression should be further evaluated and consolidated. 
In parallel, the quantification of Aβ oligomers in CSF has been carried out; even if debating data have 
been noted an overlap between the aged population and the low level of oligomers in CSF that make 
a reliable quantification challenging. Several studies have found increased Aβ oligomer levels in the 
CSF of AD patients [96-98], while other studies have reported no change [99, 100] or lower levels 
[101]. A possible explanation could reside in the selected method of detection (i.e., ELISA, Western 
Blot, ultrasensitive bead-based immunoassays) or the overlap of AD with other forms of dementia. 
Overall, these data suggest that Aβ42 detection in CSF allows for screening of early cases of AD and 
monitoring disease progression. However, this measurement constitutes only an additional test to 
confirm the disease diagnosis and provides little information on the disease progression. 
The levels of tau protein in CSF have also been considered as possible biomarkers. A significant 
enhancement in CSF tau and phospho-tau have been identified in AD patients [66, 102-104]. 
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Interestingly, the measurement of total and phospho-tau has not only been reported to identify AD 
pathology, but in combination with the Aβ measurement, it allows for the discrimination of AD from 
MCI with high accuracy [91, 105]. Moreover, autopsy studies have confirmed the association 
between high levels of CSF tau and AD severity [89], thus validating CSF tau as a biomarker of 
neuronal damage and neuronal and axonal degeneration. 
α-Syn has been widely investigated as a potential peripheral biomarker to detect the NDs and to 
discriminate between different pathologies. Decreased CSF levels of α-syn have been shown in 
primary synucleinopathies, such as DLB and PD with respect to controls [106-108]. Conversely, 
oligomeric [109] and phosphorylated α-syn [110] have been reported to be significantly increased in 
PD patients. Regarding AD, CSF α-syn levels have been demonstrated to be higher with respect to 
controls [111]. However, conflicting data regarding the use of CSF α-syn levels to discriminate 
between different NDs have been reported [112]. One of the main issues could be the difficulty in the 
detection of α-syn oligomers and phosphorylated protein. Identification of innovative methodology 
to detect toxic species could help to validate the CSF α-syn levels as a biomarker for different NDs 
[113, 114]. 
Crucial disadvantages limit the clinical diagnostic and prognostic use of CSF biomarkers, such as 
cut-off values, the absence of assay standardization, and overlap between different types of dementia. 
Importantly, CSF sample collection requires a lumbar puncture, an invasive procedure which limits 
follow-up clinical trials [115]. Thus, there is a crucial necessity for peripheral biomarkers, in 
particular for AD, that could correlate with brain lesions and establish the efficacy of therapeutic 
drugs. In particular, more appropriate and manageable tissues need to be exploited by the introduction 
of specific and sensitive diagnostic tests at lower costs.  
Great efforts have been devoted in exploiting biochemical markers in tissues other than CSF [103, 
104, 116-118]. In this respect, the use of blood cells and plasma as a source of dementia biomarkers 
has been emerging because of its availability, lower cost and time effectiveness with respect to CSF. 
Pathological changes in blood proteins have been suggested to reflect the changes in CSF due to 
barrier impairment in dementia or merely by diffusion [119]. A CSF biomarker that can be potentially 
translated to blood is Aβ. Even if plasma Aβ species have been extensively investigated, literature 
results are inconsistent. Plasma Aβ42 has been shown to increase in familial AD, while an opposite 
trend has been demonstrated during the disease-associated cognitive decline prior to the development 
of dementia [92]. Opposite results have been reported also by Hulstaert and co-workers [93]. The 
discrepancy in the quantification of Aβ could be ascribed to several reasons: i)the traffic across the 
blood-brain barrier; ii) the inability to measure Aβ oligomeric form; or iii) the use of inappropriate 
antibodies in ELISA protocols. The debate on the effective use of plasma Aβ as a biomarker is still 
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ongoing. In fact, Wood [120] stated that Aβ concentration in plasma is inappropriate to use as a 
biomarker due to the issues in detection and the interference of variables such as sex, age and other 
forms of dementia. 
Tau is a brain-specific protein that can be converted to a relevant blood biomarker. To date, little is 
known about tau levels in blood due to its low abundance. Several efforts have been made in the 
detection of tau levels in the plasma of AD patients. However, these studies have shown contradictory 
data, including increased levels [121], mild increases [122], no differences [123] or reduced levels in 
AD compared to control [124]. Recently, Mattsson and co-workers [125] have demonstrated that 
higher levels of plasma tau partially reflect AD pathology, but the overlap between normal ageing 
and AD is large, thus highlighting the need of further investigation to clarify the potential of tau as a 
biomarker in AD and other NDs. 
Interestingly, a few studies have reported the expression of high molecular tau in the platelets of AD 
patients [126, 127], but such changes do not correlate with cognitive decline [128]. Moreover, 
increased total tau levels in older AD patients compared to younger AD patients and healthy controls 
have been found, suggesting platelet tau as a diagnostic marker for the detection of disease onset 
[129].  
The data regarding plasma α-syn levels in PD patients remain controversial. Plasma α-syn has been 
shown to increase early in PD [130]; such differences are particularly relevant following elimination 
of heterophilic antibody interference [131]. Conversely, other authors report no differences between 
PD patients and controls in total plasma α-syn [132, 133]. Foulds and co-workers [134] showed no 
difference in the total and oligomeric α-syn plasma levels, but they also noted a significant increase 
in phospho-α-syn (Ser129). Peripheral α-syn will probably not be used a diagnostic marker because 
it is produced not only in the brain but also in blood cells and skin [135, 136]. Another problem is the 
sensitivity of the detection methods, similar to the issues of CSF detection. To overcome this problem, 
Yang and co-workers [137] recently presented a new method of detection with improved sensitivity 
in immunomagnetic reduction (IMR). They used magnetic nanoparticles with antibodies against α-
syn and were able to detect an increase in the protein in the plasma of PD patients. 
Very recently, researchers have detected total and oligomeric α-syn in saliva: the authors showed that 
total α-syn decreases in PD patients, whereas its oligomeric form increases in the same cohort [138]. 
Such modifications correlate with several patients’ clinical features, suggesting that the combined 
detection of total and oligomeric α-syn might aid in the early diagnosis of PD [138]. 
Although plasma Aβ, tau and α-syn have been investigated thoroughly in previous studies, little 
attention has been paid to the red blood cell (RBC) concentration of the proteins. Despite the widely 
accepted effects of Aβ on RBC function [139], few studies have reported Aβ quantification in RBCs, 
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which shows an increase in the protein with ageing and a decrease with antioxidant supplementation 
[140]. Similarly, to the best of our knowledge, no data have been reported on the quantification of tau 
in RBCs. 
Some studies have been conducted in RBCs to assess levels of α-syn oligomer and total α-syn in PD. 
It has been shown that the ratio of RBC α-syn oligomeric/total protein is higher in PD patients than 
in control subjects; however, there is no correlation between this measurement and age of onset, 
disease duration, age, motor scale score or progression of motor degeneration in PD patients [141]. 
The results are consistent with previous findings showing an elevation of α-syn oligomers in CSF and 
plasma of PD patients. Because RBCs contain high levels of α-syn and detection of RBC α-syn can 
avoid contamination arising from haemolysis, this method should be more stable and reproducible 
compared with those detecting α-syn oligomers in plasma and CSF [141].  
Other innovative approaches to detect oligomers/aggregates in peripheral fluid (CSF, plasma and 
RBC) have been recently reported by Horrocks and co-workers [142]. They developed a method of 
single aggregate visualization by enhancement imaging (SAVE) for the ultrasensitive detection of β-
sheet rich fibrils and oligomers using single-molecule fluorescence microscopy. The methods do not 
allow for the discrimination of Aβ, tau and α-syn oligomers. However, the level of total oligomers 
are higher in CSF fluid of PD patients with respect to the aged control group.  
Despite the efforts in the research of peripheral biomarkers able to detect the insurgence and the 
progression of NDs, conflicting data have been reported, which highlight the need to improve the 
accuracy and efficiency of the detection methods and the knowledge of the misfolded protein onset 
and fate.  
 
3. New insights into protein aggregation inhibition as novel targets in neurodegenerative 
diseases 
The issue of ND management is the development of therapeutic tools not only to delay worsening of 
symptoms but also to ameliorate the pathological signs. To date, there are no effective treatments that 
can prevent ND progression. Among the ND therapeutic strategies, the development of compounds 
able to prevent protein aggregation and remove diffusible toxic oligomers has been emerging (Table 
2) [143]. 
 
3.1 Aβ aggregation inhibitor 
In the last two decades, several disease-modifying strategies have been developed with the aim to decrease Aβ 
monomer production or to remove deposited Aβ [144, 145], such as the use of potent, highly selective inhibitors of β- 
and γ-secretases that can readily enter the brain and lower Aβ production. Similarly, efforts are also ongoing to develop 
small molecules that can up-regulate the enzymes that control Aβ degradation and thus lower Aβ levels by increasing 
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Aβ catabolism. The latest advances in the pharmacological inhibition of the Aβ formation or degradation enzymes have 
been extensively reviewed [144, 145].  
Recently, innovative strategies to reduce Aβ toxicity have emerged (Table 2). Particularly, small 
derivatives have been developed that are able to interfere with Aβ aggregation (i) by reducing the 
oligomerization process and/or (ii) by inducing a conformational change in β-sheet assembly and/or 
(iii) by inducing quick conversion of soluble aggregates into less toxic fibrils [145]. 
In the literature, several small-molecules have been reported to interfere with Aβ aggregation, and 
most of these molecules share polyphenolic structures [146], such as 4-aminophenol [147], 
resveratrol [148], myricetin [149], curcumin [150], caffeine [151]. 
Another therapeutic approach targets the nucleation site of aggregation. This region is known as the 
KLVFFA and is the hexapeptide sequence that is believed to facilitate monomer-monomer 
interaction, leading to dimer and oligomer formation [152, 153]. An Aβ-steric zipper has been 
established as a useful model to investigate the binding interactions of small molecules with putative 
anti-Aβ activity [154]. Additionally, a few compounds have been identified by a high-throughput 
approach and demonstrated to interact with the KLVFFA region [155].  
Among the Aβ-anti-aggregating strategies, an anti-Aβ immunotherapy approach has been emerging. 
In particular, antibodies that recognize the different toxic species of Aβ can act: i) directly by 
neutralizing them and blocking their toxic effects; ii) by stimulating microglial clearance; and/or iii) 
by promoting Aβ exit from the brain to the systemic circulation. This therapeutic approach has been 
demonstrated to decrease brain Aβ levels, reduce gliosis and neuritic dystrophy, and counteract 
memory impairment in AD transgenic mice [156]. More importantly, Alzheimer’s disease patients 
who were immunized with aggregated Aβ showed diminished cognitive decline and slowed disease 
progression compared with patients who received the placebo [157]. Unfortunately, the phase IIa trial 
employing the AN1792 Aβ vaccine was stopped when ~6% of the immunized patients developed 
meningoencephalitis [158]. Great efforts are ongoing to avoid such problems and develop an effective 
immunization protocol.  
Therapies directed at blocking Aβ oligomerization into toxic oligomers and aggregates have entered 
clinical trials. However, numerous phase II/III clinical trials for ADwith drugs targeting Aβ 
aggregation have failed [159, 160]. There are several reasons that can explain the high rate of clinical 
trial failure. Since Aβ plaque deposition may begin 10 years or more prior to the onset of cognitive 
symptoms [161, 162], one critical issue is the stage of disease generally targeted (mild-to-moderate 
dementia stages). This hypothesis is supported by the results of the solanezumab phase III trial in 
which a subgroup analysis showed a significant slowing of cognitive decline in subjects with mild 
AD dementia at baseline but not moderate AD [163]. Thus, ND drug discovery research has recently 
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shifted towards tau [164], because, in contrast to Aβ, tau pathology correlates with the degree of 
cognitive impairment and neuronal loss [165]. 
 
3.2 Tau aggregation inhibitor 
Several therapeutic approaches targeting tau aggregation have been proposed (Table 2), such as 
inhibition of tau phosphorylation (kinase inhibitors), a microtubule stabilizer, a tau aggregation 
inhibitor (TAI), immunotherapy and chaperone-based drugs targeting disease-specific tau species 
[166, 167]. Thus, the new potential natural or synthetic molecules that are able to inhibit tau 
aggregation are reviewed and discussed. 
Several small molecules developed to inhibit tau oligomer formation have already been tested in 
humans [166, 168, 169]. However, a discrepancy has been highlighted between the cell-based and/or 
in vitro data and the in vivo efficacy of TAI. In the last decade, different classes of agents able to 
interfere with tau aggregation have been reported, including but not limited to polyphenols such as 
green tea-derived (−)- epigallocatechin gallate (EGCG) [170], porphyrins such as hemin chloride 
[171], phenothiazines such as Methylene blue [171], benzothiazoles/cyanines such as N744 and 
Riluzole [172], thioxothiazolidinones (rhodanines), phenylthiazole-hydrazides, anthraquinones, and 
aminothienopyridazines (ATPZs) [167, 172] (Table 2). These compounds present two distinct 
mechanisms of action: the first includes the covalent TAIs, and the second includes the non-covalent 
inhibitors, which cause less secondary effects but also have less efficacy. Based on these scenarios, 
several clinical trials have begun. However, the most promising tau oligomer inhibitor is 
leucomethylthioninium (LMT, leucomethylene blue (MB), LMTX, TRx0237), developed by 
TauRxTherapeutics Ltd., Republic of Singapore, which is a second-generation TAI for AD treatment. 
TRx0237 shares the same active ingredient and mode of action of another first-generation TAI, 
methylthioninium (MT, Rember, TRx-0014) developed by the same company. LMTX is the reduced 
form of MT and is designed to have improved bioavailability and tolerability. They are both derived 
from methylthioninium chloride (MTC), a tricyclic phenothiazine, and they represent the most 
advanced TAIs in clinical development for the treatment of AD. Several clinical trials are currently 
ongoing for this class of compounds (ClinicalTrials.gov Identifier NCT01626391, NCT01689233, 
NCT01689246, NCT01626378, NCT02245568) for AD treatment and Behavioural Variant 
Frontotemporal Dementia (bvFTD). Overall, the trial failed to meet its primary efficacy outcome. 
However, the investigators found clinically meaningful and statistically significant reductions in the 
rate of disease progression in key study measures but only in the 15% of patients treated with LMTX 
monotherapy. These inconsistent results emphasize the issues with the use of TAI in regards to the 
stage of the pathology, similar to the amyloid inhibitor. 
17 
 
However, several other chemical entities and compounds have been reported [173-175]. Okuda and 
co-workers [173] reported a new compound, PE859 (3-[(1E)-2-(1H-indol-6-yl)ethenyl]-5-[(1E)-2-[2-
methoxy-4-(2-pyridylmethoxy)phenyl]ethenyl]-1H-pyrazole), that inhibits tau aggregation in vitro 
and delays the onset and progression of motor dysfunction in an in vivo experiment with a reduction 
of tau aggregates in the central nervous system. In parallel, Saeda and co-workers [174] demonstrated 
that 1,2-dihydroxybenzene-containing compounds (i.e., isoproterenol, dopamine, epinephrine) can 
inhibit tau oligomerization. Of note, among these compounds, isoproterenol is able to decrease tau 
formation in vivo. As an innovative therapeutic strategy, Kim and co-workers [175] reported the use 
of specific tau-binding RNA aptamers that effectively delayed tau oligomerization in vitro and in 
tauopathy model cells.  
The efforts to develop safe and efficacious anti-Aβ immunotherapy as active or passive vaccination 
have been translated to the development of immunotherapies targeting tau. Several active vaccines 
have entered clinical trials [167], such as the AADvac1 that is a synthetic peptide derived from tau 
amino acids 294 to 305 coupled to keyhole limpet hemocyanin (KLH) through an N-terminal 
cysteine, which has entered a Phase II clinical trial (ClinicalTrials.gov Identifier NCT02579252). 
Likewise, in active immunization, several antibodies have been developed directed to the 
phosphorylated sites, pS396/pS404/pS422 [176, 177]. RG7345 (RO6926496, MAb86) is a human 
monoclonal antibody specifically targeting pS422 that is able to counteract the signs of AD in a mouse 
model [177] and recently entered a phase I clinical study (ClinicalTrials.gov Identifier 
NCT02281786). 
 
3.3 α-Syn aggregation inhibitor 
In the discovery of effective inhibitors for the prevention and cure of NDs, amyloid and tau have 
received great attention with more than 4800 and 1500 papers, respectively, in PubMed. Recently, 
the development of molecules able to prevent the deposition of the toxic protein, α-syn, have arisen 
as an attractive therapeutic approach (Table 2) [178]. The reported inhibitors could be grouped into 
three categories: 1) small synthetic molecules and natural polyphenols, 2) peptides, and 3) aryl-
residue-rich β-hairpins with no sequence homology to α-syn. 
Polyphenols are a large group of aromatic compounds containing one or more phenolic hydroxyl 
groups. Among this class of compounds, baicalin [179], EGCG [180, 181], tannic acid (TA) [182], 
resveratrol [183] and curcumin [184] have been found to potently inhibit the assembly of α-syn into 
multimeric oligomers. Almost all these compounds reveal their effects only in preclinical studies. 
However, a phase III clinical study on the effect of EGCG as a neuroprotective agent is currently 
ongoing but not recruiting participants (ClinicalTrials.gov Identifier NCT02008721). 
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Among the synthetic molecules, NPT200-11 [185] and ANLE138b [186, 187] are emerging as 
promising candidates for PD treatment. Both compounds are able to pass the blood–brain barrier and 
have been reported to modify and thus reduce the aggregation of α-syn in preclinical studies [185]. 
Furthermore, NPT200-11 recently completed a phase I clinical trial (ClinicalTrials.gov Identifier 
NCT02606682) and exhibited low toxicity in healthy volunteers, thus opening the way for the 
experimentation on PD patients.  
In the panel of disease-modifying therapies, the use of small peptides to control oligomerization has 
been on the rise. It has been widely accepted that the 71-82 region of α-syn is the site of aggregation. 
In light of this finding, several efforts have been made in the design and synthesis of β-sheet breakers 
based on this region. These efforts led to the discovery of unmodified peptides [188] and N-
methylated peptides [189]. Nevertheless, the effects of the synthetic peptides in vitro have no data 
available in clinical trials. However, the research of effective peptides that target not only the 
aggregation site but also other pivotal sites for the correct folding of the protein is still ongoing [190, 
191]. 
Another approach is active or passive immunization therapy that is based on the use of α-syn 
antibodies, as described for AD therapy [192]. Recently, a vaccine composed of short immunogenic 
peptides that mimic the C-terminus of α-syn (PD01A, AFFITOPE®, AFFiRiS) has been developed 
[193]. The vaccine results showed that it was well tolerated,  and the next step (AFF008AA) is 
focusing on the long-term safety and the assessment of the immunological and clinical effects of a 
second vaccination ("reboost"). The results are expected in 2017.  
Similarly, PRX002 is a monoclonal antibody able to bind the oligomeric form of α-syn. It is safe and 
well tolerated, as demonstrated by the positive results of a phase I, double-blind placebo clinical trial 
in healthy subjects conducted in 2014 (ClinicalTrials.gov Identifier NCT02095171). Based on these 
encouraging findings, another phase I study of multiple ascending doses has been initiated in patients 
with recent onset PD (ClinicalTrials.gov Identifier: NCT02157714).  
A new frontier in immunotherapy is represented by the discovery and development of antibodies 
against the phosphorylated site of α-syn [194]. The phosphorylation of Ser129 seems to be a critical 
event in the accumulation of α-syn in the brain [195]. Thus, the development of a specific pSer129 
antibody could represent an innovative target not only for imaging but also for the reduction of α-syn 
oligomerization. 
Despite the efforts in the discovery and development of inhibitors of the transition to insoluble 
deposits of Aβ, α-syn and tau protein, several clinical trials have failed. One explanation could be the 
inadequacy of the disease-modifying strategy, however, in some cases, the use of the compounds was 
able to stabilize the non-toxic species preventing further polymerization. An example is Diflunisal, a 
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drug that can stabilize the mutant transthyretin (TTR) tetramer, which is one of the causes of familial 
amyloid polyneuropathy [196, 197]. Another possible explanation of the aggregation inhibitor failure 
is the stage of the disease during the drug administration. In fact, several clinical trials demonstrated 
positive outcomes in a subgroup of subjects. This evidence suggests that ND treatment should be 
initiated prior to the onset of clinical symptoms [198]. In accordance, the aggregate inhibitor should 
be used depending on the ND stage. 
 
3.4 Broad-spectrum inhibitor 
Recently, the synergy between Aβ, tau and α-syn in the acceleration of NDs has been highlighted [36, 
41, 199]. Moreover, the discovery of heteromonomers and heteroaggregates supports the strategy to 
use broad-spectrum compounds that can interfere with the aggregation of more than one protein. 
Umeda and co-workers [199] reported that rifampicin, a well-known antibiotic, is able to prevent the 
aggregation of Aβ, tau and α-syn in a cell-free model. Moreover, they demonstrated that the drug can 
reduce Aβ and tau deposition in a mouse model of AD and reduces memory impairment. These 
findings are leading the way for the use of broad-spectrum compounds in the prevention of NDs and 
highlight the need to develop new effective anti-aggregation agents. 
 
4. Future directions 
In this review, the link between protein misfolding/aggregation and neurodegeneration was 
summarized, and the main pharmacological and clinical evidence at the basis of such a hypothesis 
were reported. Nevertheless, in the intensive research of aggregate-based biomarkers, most of the 
biomarkers demonstrate group differences but cannot reliably diagnose AD or PD in their early stages 
in an individual subject. This issue can be ascribed to an imprecise diagnosis that depends on clinical 
or pathological features, as well as phenotypic convergence, indicating the limit of the current 
understanding of NDs. Further efforts are needed to investigate and validate predictive biomarkers, 
in particular for the preclinical phase of neurodegeneration. In this scenario a greater attention have 
been directed to the heteroaggregates. The level of hetereoaggregates seem to be related to the 
progression of NDs thus highlighting their use a possible central and peripheral biomarker. Even if, 
further studies are mandatory to clarify their role in the unset and progression of NDs. 
Of the therapeutic strategies targeting protein aggregates, the most appropriate and effective strategies 
will be selected depending on the nature of the target protein (e.g., intrinsically or natively disordered, 
whether it forms extracellular or intracellular deposits), as well as the disease stage. Unfortunately, 
the same lack of biomarkers for early diagnosis impedes the monitoring of the pharmacological 
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response to therapies. We expect that new biomarkers will be identified through basic research 
focused on quantifying all the aggregates present before and after clinical symptom presentation.  
Alternatively, new insights into the pathological role of heteromonomers and heteroaggregates could 
pave the way for the discovery and development of an aggregation inhibitor able to decrease 
neurodegeneration and possibly overcome the current barriers in disease-modification strategies. 
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Figure Legend 
 
Fig. 1. Aβ, α-syn and tau production and aggregation. The monomers originate from different 
pathways. The Aβ monomer originates from the proteolytic activity of a secretase that leads to the 
production of the amyloidogenic fragment Aβ. The α-syn structure is characterized by three distinct 
regions: the N-terminal region (residues 1–60), the central region (residues 61–95) known as the non-
amyloid component (NAC), and the C-terminal hydrophilic region that represents a different 
phosphorylation site (Ser129). Tau is a protein that stabilizes microtubules, and its 
hyperphosphorylation leads to the production of tau filaments that can form different types of 
aggregates. The pivotal mechanisms of monomer and oligomer degradation are mediated by the 
lysosomal/phagosomal machinery and proteasomal degradation. The monomers interact with each 
other to create oligomers and aggregates. The monomers of different proteins could also interact, 
producing heteromonomers and heteroaggregates. 
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Table 1. Aβ, tau and α-syn as potential biomarkers in central and pheripheral fluids.  
 
 Diagnostic  
site 
Diagnostic 
sign 
Metodology of detection References 
Central 
Aβ Post-mortem human brain SP Immunohistochemical, Congo 
red 
[66] 
Post-mortem human brain Aβ-deposit Fluorescent microscopy, 
Thioflavin-T (ThT) 
[67] 
Human brain β-sheet structure, SP PET, [18F]-FDDNP [68] 
Human brain β-sheet structure, SP PET, [11C]-PiB [69] 
Human brain SP PET, [18F]-florbetapir, [18F]-
flutemetamol, [18F]-
florbetaben 
[76-78] 
AD mice Aβ-deposit MRI, [19F]-XP7, [19F]-
FMeC1, [19F]-FSB 
[71-75] 
Metabolic deficiencies of AD Neuronal function PET, [18F]-FDG  [79-80] 
tau Human brain NFT PET, [11C]-PBB3 [86] 
Human brain NFT PET ,[18F]-THK-5351, [18F]-
AV1451 
[87-89] 
Human brain section NFT SPECT [125I]-phenylethenyl 
benzimidazole 
[90] 
α-syn Macaque brain LB, LN PET, [18F] 3-(2-fluoroethoxy)-
7-nitro-10H-phenothiazine 
[93] 
Peripheral 
Aβ CSF Total Aβ42 ELISA [94,95] 
CSF Aβ40/Aβ42 ELISA [96,97] 
CSF Aβ oligomers ELISA, Western-Blot [102-107] 
Plasma Total Aβ42 ELISA [98,99] 
RBC Aβ40/Aβ42 ELISA [152] 
tau CSF tau, phospho-tau ELISA [108-111] 
Plasma Total tau  ELISA, Western-Blot [130-136] 
Platelet tau oligomers ELISA [139,140] 
α-syn CSF Total α-syn ELISA, Western-Blot [112-114, 
119,120] 
CSF α-syn oligomers ELISA [115,116] 
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CSF phospho-α-syn ELISA [117,118] 
Plasma Total α-syn ELISA [141-144] 
Plasma phospho-α-syn ELISA [145] 
Plasma Total α-syn IMR [148] 
RBC Total/oligomeric α-syn ELISA [150] 
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Table 2. Aβ, tau and α-syn aggregate inhibitors.  
 
Protein Compound Stage of 
development 
Structure References/ 
Clinical Trials 
Aβ Smal molecules 
4-aminophenol pre-clinical 
OH
NH2
 
[158] 
Resveratrol pre-clinical 
OH
OH
OH
 
[159,160] 
Myrecetyn pre-clinical 
OH
OH O
O
OH
OH
OH
OH
 
[161] 
Curcumine pre-clinical O O
OH
O O
OH
 
[162,163] 
Caffeine pre-clinical 
N
N N
N
O
O
 
[164,165] 
Immunization therapy 
AN1792 phase IIa (Failed)  [172] 
tau  Smal molecules 
Epigallocatechin 
gallate, EGCG 
pre-clinical 
O
O
O
OH
OH
OH
OH
OH
OH
OH
OH
 
[184] 
Hemin chloride pre-clinical 
Cl
N N
N N
O
OHOH
O
Fe
-
 
[185] 
Methylene blue pre-clinical N
SN N
+
Cl-
 
[185] 
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N744 pre-clinical 
S
N
+
OH
N
S
OH
O O
 
[186] 
Riluzole pre-clinical S
N
O
CF3NH2
 
[186] 
TRx0237 
(LMT, 
leucomethylene blue, 
LMTX) 
Phase II/III 
N
H
SN
+
N
+
H H
CH3SO3
-
CH3SO3
-
 
NCT01626391N
CT01689233NC
T01689246NCT0
1626378NCT022
45568 
PE859  pre-clinical 
N
O
O
N
H
N NH
 
[187] 
Isoproterenol pre-clinical OH
NHOH
OH  
[188] 
Immunization therapy 
AADvac1 Phase II  NCT02579252 
RG7345 
(RO6926496, 
MAb86) 
Phase I  NCT02281786 
[191] 
α-syn Smal molecules 
Baicalin  pre-clinical 
O
OH
OH
O
O
O
OH
OH
OH
O
OH
 
[193] 
Epigallocatechin 
gallate (EGCG)  
pre-clinical 
Phase III 
O
O
O
OH
OH
OH
OH
OH
OH
OH
OH
 
[194,195] 
Tannic acid (TA)  pre-clinical 
OO
O
O O
O
OO
OH
OH
OH
OH
OH
O
O
O
OH
OH
OH
OH
OH
O O
OH
OHO
O
OH
OH
OH
O
O
OH
OH
OH
OH
OH
O
OH
OH
O
O
OH
OH
OH
 
[196] 
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Resveratrol   pre-clinical 
OH
OH
OH
 
[197] 
Curcumine pre-clinical O O
OH
O O
OH
 
[198] 
NPT200-11  Phase I  NCT02606682 
[199] 
ANLE138b pre-clinical 
O
O
N N
H
Br
 
[200,201] 
Immunotherapy therapy 
PD01A 
(AFFITOPE®, 
AFFiRiS) 
Phase I  [207] 
PRX002 Phase I  NCT02095171 
NCT02157714 
Broad 
inhibitor 
Smal molecules 
Rifampicin Pre-clinical 
OH OH
NH
N
N
NOH
O
O
O
OH
OHO
O
O
O
 
[213] 
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